The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial

Quality of Life Research

Volumn 14, Issue 5, 2005, Pages 1275-1289

  Kilian, Reinhold ^a,b   Angermeyer, Matthias C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

HRQL; Neuroleptic treatment; Propensity scores; Prospective observational design; Random effect regression; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZATION; SCHIZOPHRENIA; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GERMANY; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUALITY OF LIFE; SCHIZOPHRENIA; SICKNESS IMPACT PROFILE; TIME FACTORS;

EID: 21244503152     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-004-5533-x     Document Type: Article

References (62)

1. WM Glazer 2000 Expected incidence of tardive dyskinesia associated with atypical antipsychotics J Clin Psychiatr 61 Suppl 4 21 26
2. T Burns R Bale 2001 Clinical advantages of amisulpride in the treatment of acute schizophrenia J Int Med Res 29 451 466
3. J Bobes M Gutiérrez J Gibert HL González A Fernández 1998 Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment Eur Psychiatr 13 158 163
4. AG Awad YD Lapierre C Angus A Rylander 1997 Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride J Psychiatry Neurosci 4 244 248
5. SH Hamilton DA Revicki LA Genduso 1998 Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial Neuropsychopharmacol 18 41 49
6. SH Hamilton DA Revicki ET Edgell LA Genduso 1999 Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia.Results from a randomized clinical trial Pharmacoecon 15 469 480
7. J Stallard E Joyce 2001 The impact of olanzapine on attitude to medication and quality of life in schizophrenia Psychiatr Bull 25 378 381
8. M Ritsner A Ponizovsky J Endicott 2002 The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study Eur Psychopharmacol 12 31 38
9. AG Awad TP Hogan LPN Voruganti RJ Heslegrave 1995 Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life Int Clin Psychopharm 10 Suppl 3 123 132
10. AG Awad 1993 Subjective response to neuroleptics in schizophrenia Schizoph Bull 19 609 618
11. S Browne J Garavan M Gervin M Roe C Larkin E O'Callahan 1998 Quality of life in schizophrenia: Insight and subjective response to neuroleptics J Nerv Ment Dis 186 74 78
12. M Doyle S Flannagan S Browne 1999 Subjective and external assessments of quality of life in schizophrenia: relationship to insight Acta Psychiatr Scand 99 466 472
13. F Holloway F Carson 1999 Subjective quality of life, psychopathology, satisfaction with care and insight: an exploratory study Int J Soc Psychiatr 45 259 267
14. HC van Houwelingen 1997 The future of biostatistics: Expecting the unexpected Stat Med 16 2773 2784
15. S Gilbody K Wahlbeck C Adams 2002 Randomized controlled trials in schizophrenia: A critical perspective on the literature Acta Psychiatr Scand 105 243 251
16. M Slade S Priebe 2001 Are randomized controlled trials the only gold that glitters? Br J Psychiatry 179 286 287
17. AD McMahon 2002 Study control, violators, inclusion criteria and defining explanatory and pragmatic trials Stat Med 21 1365 1376
18. JM Haro ET Edgell PB Jones 2003 The European schizophrenia outpatient health outcomes (SOHO) study: Rationale, methods and recruitment Acta Psychiatr Scand 107 222 232
19. M Franz T Meyer T Reber B Gallhofer 2000 The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients Qual Life Res 9 481 489
20. NT Longford 1999 Selection bias and treatment heterogeneity in clinical trials Stat Med 18 1467 1474
21. JM Wooldridge 2002 Econometric Analysis of Cross Section and Panel Data MIT Press Cambridge
22. Wh Crown RL Obenchain L Englehart T Lair DP Buesching T Croghan 1998 The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization Stat Med 17 1943 1958
23. D'Agostino 1998 Tutorial in biostatistics.Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 2265 2281
24. H Häfner W ander Heiden 1999 The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies Eur Arch Psychiatr Clin Neurosci 249 IV/14 IV/26
25. G Harrison K Hopper T Craig 2001 Recovery from psychotic illness: A 15- and 25-year international follow-up study Br J Psychiatry 178 506 517
26. W an der Heiden H Häfner 2000 The epidemiology of onset and course of schizophrenia Eur Arch Psychiatr Clin Neurosci 250 292 303
27. S Browne 1999 Rehabilitation programmes and quality of life in severe mental illness Int J Soc Psychiatr 45 302 309
28. L Colonna P Saleem L Dondey-Nouvel W Rein 2000 Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia Int Clin Psychopharm 15 13 22
29. B-C Ho P Nopoulos M Flaum S Arndt NC Andreasen 1998 Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life Am J Psychiatr 155 1196 1201
30. J Russo P Roy-Byrne D Reeder 1997 Longitudinal assessment of quality of life in acute psychiatric inpatients: Reliability and validity J Nerv Ment Dis 185 166 175
31. RE Taylor M Leese P Clarkson F Holloway G Thornicroft 1998 Quality of life outcomes for intensive versus standard community mental health services. PRiSM Psychosis Study 9 Br J Psychiatry 173 416 422
32. RD Gibbons D Hedeker I Elkin 1993 Some conceptual and statistical issues in analysis of longitudinal psychiatric data.Application to the NIMH treatment of depression collaborative research program dataset Arch Gen Psychiatr 50 739 750
33. EW Lambert A Doucette L Bickman 2001 Measuring mental health outcomes with pre-post design J Behav Health Serv Res 28 273 286
34. BH Baltagi 2001 Econometric Analysis of Panel Data Chichester, New York John Wiley & Sons
35. JD Huppert TE Smith 2001 Longitudinal analysis of subjective quality of life in schizophrenia: Anxiety as the best symptom predictor J Nerv Ment Dis 180 669 675
36. K Jinnet JA Alexander E Ullmann 2001 Case management and quality of life: Assessing treatment and outcomes for clients with chronic and persistent mental illness Health Serv Res 36 61 90
37. M Besthehorn B Tischer P Glaser O Mast D Schmidt 1999 Representative study on the distribution of schizophrenia patients to medical health care institutions in Germany Fortschr Neurol Psychiatr 67 487 492
38. JK Wing T Babor T Brugha 1990 SCAN: Schedules for Clinical Assessment in Neuropsychiatry Arch Gen Psychiatr 47 589 593
39. JE Ware B Gandek 1994 The SF-36 Health Survey: Development and use on mental health research and the IQOLA Project Int J Ment Health 23 49 73 the IQOLA Project Group
40. CJ Meijer AH Schene MWJ Koeter 2002 Quality of life in schizophrenia measured by the MOS SF-36 and the Lancashire Quality of Life Profile: a comparison Acta Psychiatr Scand 105 293 300
41. D Chisholm M Knapp HC Knudsen 2000 Client Sociodemographic and Service Receipt Inventory- European Version Br J Psychiatry 177 (Suppl 39 S28 S33
42. SR Kay LA Opler JP Lindemeyer 1989 The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation Br J Psychiatry 155 59 65
43. D Addington J Addington B Schissel 1990 Reliability and validity of a depression rating scale for schizophrenia Schizophr Res 3 247 251
44. American Psychiatric Association. 1987 Diagnostic and statistical manual of mental disorders (DSM-III-R) 3 APA Washington DC
45. T Barnes 1989 A rating scale for drug-induced akathisia Br J Psychiatry 154 672 676
46. G Simpson J Angus 1970 A rating scale for extrapyramidal side effects Acta Psychiatr Scand 212 11 19
47. W Guy 1976 ECDU Assessment Manual for Psychopharmacology Rockville MD
48. O Lingjaerde U Ahlfors P Bech S Dencker K Elgen 1987 The UKU side effect rating scale Acta Psychiatr Scand 334 (Suppl 1 100
49. C Taft J Karlsson M Sullivan 2001 Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res 10 395 404
50. E Ware J M Kosinski SD Keller 1994 SF-36 Physical and Mental Health Summary Scales - A User's Manual New England Medical Center, The Health Institute Boston,MA
51. BH Baltagi PX Wu 1999 Unequal spaced panel data regressions with AR(1) disturbances Econometr Theory 15 814 823
52. Stata Corporation 2001 Stata Reference Manual. Release 7 Stata Press College Station
53. WH Greene 2003 Econometric Analysis 5 Upper Saddle River Prentice Hall
54. D Hedeker JS Gibbons C Waternaux 1999 Sample size estimation for longitudinal designs with attrition: Comparing time-related constrasts between two groups J Educ Beha Stat 24 70 93
55. D Naber S Moritz M Lambert 2001 Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs Schizophr Res 50 79 88
56. D Naber A Karow M Lamber 2002 Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration Curr Opin Psychiatry 15 31 36
57. MZ Dermovsek VP Rupel M Rebolj R Tavcar 2001 Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics Eur Psychiatr 16 474 482
58. U Zimmermann T Kraus H Himmerich A Schuld T Pollmächter 2003 Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients J Psychiatr Res 37 193 220
59. LS Godleski LJ Goldsmith WV Vieweg NC Zettwoch DM Stikovac SJ Lewis 2003 Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia J Clin Psychiatr 64 119 122
60. UK 700 Group 1999 Predictors of quality of life in people with severe mental illness. Study methodology with baseline analysis in the UK 700 trial Br J Psychiatry 175 426 432
61. L Gaite JL Vázques-Barquero C Borra 2002 Quality of life in patients with schizophrenia in five European countries: the EPSILON study Acta Psychiatr Scand 105 283 292
62. M Ruggeri R Gater G Bisoffi G Barbui M Tansella 2002 Determinants of subjective quality of life in patients attending community-based mental health services.The South-Verona Outcome Project Acta Psychiatr Scand 105 131 140